Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Key Takeaways Moderna reported a larger loss than analysts had expected for the fourth quarter on Friday.The COVID vaccine ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Friday reported a loss of $1.12 billion in its fourth quarter. On a per-share basis, the Cambridge, Massachusetts-based company ...

Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...

Moderna (NASDAQ:MRNA) shares fell ~5% in the premarket on Friday after the COVID-19 vaccine maker, with its Q4 2024 results, topped the consensus for revenue but missed Street forecasts for ...

Moderna's revenue for 2024 declined by 53% compared to the previous year. The company reported a net loss of 3.6 billion dollars. Moderna's stock experienced a 5.03% drop in premarket trading ...